New hope for tough stomach cancers? early drug trial begins
NCT ID NCT07462923
Summary
This is an early-stage study testing a new drug called HS-20093 for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors. About 40 participants will receive the drug through an IV every few weeks until their cancer progresses or they experience significant side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.